Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay

Abstract

Objectives: Detection of a-synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of a-synuclein measures could inform optimal biomarker development. The objectives were to test accuracy of a-synuclein seed amplification assay in central (cerebrospinal fluid) and peripheral (submandibular gland) sources, compare to total a-synuclein measures, and investigate within-subject relationships. Methods: The Systemic Synuclein Sampling Study aimed to characterize a-synuclein in multiple tissues and biofluids within Parkinson disease subjects (n = 59) and compared to healthy controls (n = 21). Motor and nonmotor measures and dopamine transporter scans were obtained. Four measures of a-synuclein were compared: seed amplification assay in cerebrospinal fluid and formalin-fixed paraffin-embedded submandibular gland, total a-synuclein quantified in biofluids using enzyme-linked immunoassay, and aggregated a-synuclein in submandibular gland detected by immunohistochemistry. Accuracy of seed amplification assay for Parkinson disease diagnosis was examined and within-subject a-synuclein measures were compared. Results: Sensitivity and specificity of a-synuclein seed amplification assay for Parkinson disease diagnosis was 92.6% and 90.5% in cerebrospinal fluid, and 73.2% and 78.6% in submandibular gland, respectively. 25/38 (65.8%) Parkinson disease participants were positive for both cerebrospinal fluid and submandibular gland seed amplification assay. Comparing accuracy for Parkinson disease diagnosis of different a-synuclein measures, cerebrospinal fluid seed amplification assay was the highest (Youden Index = 83.1%). 98.3% of all Parkinson disease cases had ≥1 measure of a-synuclein positive. Interpretation: a-synuclein seed amplification assay (cerebrospinal fluid>submandibular gland) had higher sensitivity and specificity compared to total a-synuclein measures, and within-subject relationships of central and peripheral a-synuclein measures emerged.

Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians

“…Salivary α-syn has been investigated in PD [ 155 ], but there are no published studies investigating salivary biomarkers in pDLB or DLB. Early trials also show that biopsy of the submandibular gland is promising [ 156 ] but requires further investigation.…”

Parkinson's disease: Still waiting for a cure

“…At the MJFF PPMI meeting, I could sense a newfound energy among the participants where biology constructs of disease outweighed symptomatic intervention. The adoption of an alpha synuclein seed amplification assays (a‐syn) 13 along with DAT imaging 14 as biomarkers, combined with a new integrated Parkinson's biological staging system for research 15 has opened a new era for developing new interventions, some that may have disease modifying potential.…”

Role of Specific Autoantibodies in Neurodegenerative Diseases: Pathogenic Antibodies or Promising Biomarkers for Diagnosis

“…Gathering neuronal α-syn aggregates is a central process in the pathogenesis of Parkinson's disease (PD) [69]. These aggregates are found in the substantia nigra pars compacta in PD patients but can also be found in different neurons in the CNS and peripheral nervous system (PNS) [70]. The most extensive and highly structured forms of α-syn aggregate are Lewy bodies, either dense or diffuse structures [71,72].…”